NANCY A. DIMARTINO, MD

LAFAYETTE, IN

Research Active
Internal Medicine - Hematology & Oncology NPI registered 21+ years 2 publications 1993 – 1995 NPI: 1780687152
Internal Medicine - Hematology & Oncology
CisplatinAntineoplastic Combined Chemotherapy ProtocolsLung NeoplasmsCarcinoma, Non-Small-Cell LungDose-Response Relationship, DrugEtoposideDrug Administration ScheduleMitomycin

Practice Location

1345 UNITY PL
LAFAYETTE, IN 47905-5762

Phone: (765) 446-5050

What does NANCY DIMARTINO research?

Dr. DiMartino studies advanced stages of cancer, specifically focusing on colorectal cancer and non-small cell lung cancer (NSCLC). She investigates various chemotherapy combinations to determine how well they work for patients who have already tried other treatments. For colorectal cancer, she examined a combination of three drugs—vinorelbine, 5-fluorouracil, and folinic acid. For NSCLC, she explored a high-dose approach with cisplatin, etoposide, and mitomycin C. Her research helps patients understand the potential benefits and risks of these therapies.

Key findings

  • In her colorectal cancer study, nearly 21% of patients experienced a reduction in tumor size, and about 46% had stable disease status.
  • Patients with colorectal cancer treated with the three-drug combination had an average survival of about 6 months.
  • In the NSCLC study, 41% of patients responded to treatment, with one patient achieving complete remission.
  • NSCLC patients had a median survival of 38 weeks after receiving a high-dose chemotherapy regimen.
  • The most common side effects reported included severe nerve damage and issues related to blood cell production.

Frequently asked questions

Does Dr. DiMartino study colorectal cancer?
Yes, Dr. DiMartino studies treatments for advanced colorectal cancer specifically.
What types of cancer has Dr. DiMartino researched?
Dr. DiMartino has researched advanced colorectal cancer and non-small cell lung cancer.
What treatments has Dr. DiMartino investigated?
She has investigated combinations of chemotherapy drugs like 5-fluorouracil, vinorelbine, cisplatin, etoposide, and mitomycin C.
Is Dr. DiMartino's work relevant to lung cancer patients?
Yes, her research provides valuable insights into treatment options for patients with advanced non-small cell lung cancer.
What are the common side effects of the treatments studied by Dr. DiMartino?
Common side effects include severe nerve damage and decreased blood cell production.

Publications in plain English

A phase-ii trial of 5-Fluorouracil, folinic Acid, vinorelbine in pretreated patients with metastic colorectal-cancer.

1995

Oncology reports

Iaffaioli R, Facchini G, Tortoriello A, Caponigro F, Gesue G +8 more

Plain English
This study looked at a treatment combining three drugs—vinorelbine, 5-fluorouracil, and folinic acid—in 43 patients with advanced colorectal cancer who had already received other treatments. The researchers found that nearly 21% of patients showed a reduction in their cancer size, while about 46% had stable disease for a while. On average, patients lived for about 6 months after starting this treatment, and the most common side effect was a decrease in blood cell production. Who this helps: This research benefits patients with advanced colorectal cancer who need new treatment options.

PubMed

Treatment of advanced non-small cell lung cancer with very high-dose cisplatin combined with etoposide and mitomycin C.

1993

Cancer

Hesketh PJ, Tansan S, Caguioa PB, Hesketh A, Blanchard R +2 more

Plain English
This study explored a new high-dose chemotherapy treatment for advanced non-small-cell lung cancer (NSCLC) using a combination of cisplatin, etoposide, and mitomycin C in 41 patients. The results showed that 41% of patients responded positively to the treatment, with one achieving complete remission and the rest experiencing partial improvements. However, while patients had a median survival of 38 weeks, the treatment was also associated with significant side effects, including severe nerve damage and blood-related issues. Who this helps: This research benefits patients with advanced non-small-cell lung cancer and their doctors by providing insights into treatment effectiveness and side effects.

PubMed

Frequent Co-Authors

R Iaffaioli G Facchini A Tortoriello F Caponigro G Gesue A Finizio G Desena B Antonelli G Scaramellino L Fei

Physician data sourced from the NPPES NPI Registry . Publication data from PubMed . Plain-English summaries generated by AI. Not medical advice.